Supira Medical Announces FDA Approval for SUPPORT II Pivotal Trial, Advances in Cardiogenic Shock, and Appointment of D. Keith Grossman to Board of Directors
- Written by PR Newswire
![]() |
Milestones underscore clinical progress and strengthen commercial foundation
LOS GATOS, Calif., April 8, 2026 /PRNewswire/ -- Supira Medical, Inc. (Supira), a clinical-stage company focused on transforming the percutaneous ventricular assist device (pVAD) market, today announced FDA approval to initiate the SUPPORT II Pivotal Trial. The...















